GLP-1

The publication of two SURPASS-3 substudies in The Lancet Diabetes & Endocrinology

The publication of two SURPASS-3 substudies in The Lancet Diabetes & Endocrinology reveals significant benefits of tirzepatide on liver and abdominal fat in people with type 2 diabetes, as well as on time in target glucose range.

Tirzepatide increased time in target blood glucose.
It also decreased hypoglycemia compared to InsulinDegludec in the SURPASS-3 CGM sub-study.

-GLP-1

© 2022 船橋市の糖尿病内科 | しもやま内科